4:51 pm Novartis AG confirms FDA approval for Zykadia, first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib – HedgeChatter

4:51 pm Novartis AG confirms FDA approval for Zykadia, first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib

30 Apr

4:51 pm Novartis AG confirms FDA approval for Zykadia, first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib

Bystocknews NVS, stock Comments Off

View todays social media effects on NVS

View the latest stocks trending across Twitter. Click to view dashboard

See who Novartis is hiring next, click here to view

Author